(thirdQuint)A Thorough QT/QTc Study to Evaluate the Effects of an Intravenous Infusion of Eravacycline (TP-434) on Cardiac Repolarization.

 Each of the following treatments will be evaluated on Day 1 of each period in a crossover fashion.

 The IV eravacycline (TP-434) and IV placebo will be double-blinded.

 - Treatment A: Eravacycline (TP-434) 1.

5 mg/kg administered intravenously over 60 minutes and one placebo oral tablet; - Treatment B: Placebo (0.

9% sodium chloride) administered intravenously over 60 minutes and one moxifloxacin 400 mg oral tablet; and - Treatment C: Placebo (0.

9% sodium chloride) administered intravenously over 60 minutes and one placebo oral tablet.

 Subjects will be randomized to a treatment sequence according to a pre-generated treatment scheme.

 Subjects will receive a different treatment during each of the 3 periods.

.

 A Thorough QT/QTc Study to Evaluate the Effects of an Intravenous Infusion of Eravacycline (TP-434) on Cardiac Repolarization@highlight

This is a randomized, placebo- and positive-controlled (moxifloxacin), 3-period, 3-way crossover thorough QT study, which includes a Screening Period, Treatment Periods (1 through 3), and a Follow-up Visit.

 Subjects will be confined to the investigational site for 4 nights/3 days during Period 1 and for 3 nights/2 days during Periods 2 and 3.

 There will be a minimum of a 14 day washout between treatments.

